cdc-coteauxdegaronne
» » Productivity of Health Care and Pharmaceuticals: An International Comparison
eBook Productivity of Health Care and Pharmaceuticals: An International Comparison ePub

eBook Productivity of Health Care and Pharmaceuticals: An International Comparison ePub

by H. E. Frech III,Richard D. Miller

  • ISBN: 0844771244
  • Category: Administration and Medicine Economics
  • Subcategory: Medicine
  • Author: H. E. Frech III,Richard D. Miller
  • Language: English
  • Publisher: Aei Press; 1st US - 1st Printing edition (January 1, 1999)
  • Pages: 108
  • ePub book: 1106 kb
  • Fb2 book: 1214 kb
  • Other: docx rtf doc mbr
  • Rating: 4.6
  • Votes: 131

Description

Frech III, Richard D. Miller Jr.

See a Problem? We’d love your help.

Frech, H. E. III. Miller, Richard D. J. & Frech, Ted, 2002

Frech, H. Jr. Registered: Harry E. Frech. & Frech, Ted, 2002. The Productivity of Health Care and Pharmaceuticals: Quality of Life, Cause," University of California at Santa Barbara, Economics Working Paper Series qt4b55f1xp, Department of Economics, UC Santa Barbara. Peter Zweifel & Lukas Steinmann & Patrick Eugster, 2005. The Sisyphus Syndrome in Health Revisited," International Journal of Health Economics and Management, Springer, vol. 5(2), pages 127-145, June. William Comanor & H. Frech & Richard Miller, 2006

Frech, . Pharmaceuticals and Health Policy: International Perspectives on Provision and Control of Medicines . Blum, Richard; eds.

Health; Health Care; Sociology of Health Care; Drugs and Drug Industry; International and Political Dimensions of Biology and Medicine; Health Care for Particular Diseases or Groups; Collections. EthxWeb: Literature in Bioethics. (1981).

International Pharmaceutical Services: The Drug Industry and Pharmacy Pract. Topics in Pharmaceutical Sciences, 1983: Proceedings of the 43rd Internatio. Quality Assurance of Pharmaceuticals. Updated 2011: A Compendium of Guideli. Pharmaceutical Chemistry: Drug Synthesis v. 1. International Productivity and Competitiveness. Innovation and the Pharmaceutical Industry: Critical Reflections on the Vir. International Perspectives.

In this sequel to their 1999 book, The Productivity of Health Care and Pharmaceuticals: An International Comparison .

In this sequel to their 1999 book, The Productivity of Health Care and Pharmaceuticals: An International Comparison, Richard D. and H. Frech III extend their analysis to quality of life, disease-specific life expectancy, and the impact of obesity.

This volume contradicts the commonly-held belief that, among rich countries, the marginal return from pharmaceutical consumption is negligible. Frech III and Richard D.

Frech III HE, Miller Jr RD. The productivity of health care and pharmaceuticals: an international comparison. Babazono A, Hillman AL. Acomparison of international health outcomes and healthcare spending

Frech III HE, Miller Jr RD. Washington DC: American Enterprise Institute Press, 1999Google Scholar. Acomparison of international health outcomes and healthcare spending. Int J Technol Assess Healthcare 1994; 10 (3): Scholar. 10. Peltzman S. Regulation and health: the case of mandatory prescriptions and an extension. Managerial Decis Econ 1987 Mar ; 8 (1): 41-6CrossRefGoogle Scholar.

Поиск книг BookFi BookSee - Download books for free. Health Care Matters: Pharmaceuticals, Obesity, and the Quality of Life. Christof Schaefer, Paul . Peters, Richard K Miller. Категория: Медицина, Фармакология.

Поиск книг BookFi BookFi - BookFinder. Download books for free. Скачать (PDF) . Читать.

For example, between 1970 and 2002 these expenditures grew . times faster than GDP in the . . times faster than GDP in Germany, and . times faster than GDP in Japan. While there are many international comparisons on the impact of demographic changes on future healthcare expenditures, there are few such comparisons with regard to the impact of demographic changes on future healthcare funding. The purpose of this article is to analyse the impact of demographic changes on healthcare expenditures and funding in 14 selected EU Member States.

This volume contradicts the commonly-held belief that, among rich countries, the marginal return from pharmaceutical consumption is negligible.